| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H-O Jin, S-K Seo, Y-S Kim, S-H Woo, K-H Lee, J-Y Yi, S-J Lee, T-B Choe, J-H Lee, S An, S-I Hong, I-C Par. TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1. Oncogene. vol 30. issue 35. 2011-10-14. PMID:21460850. |
redd1 is a negative regulator of mtor, mediating dissociation of 14-3-3 from tuberous sclerosis complex (tsc)2, which allows formation of a tsc-tsc2 complex. |
2011-10-14 |
2023-08-12 |
human |
| Sandrine Benhamron, Boaz Tiros. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. European journal of immunology. vol 41. issue 8. 2011-10-03. PMID:21674478. |
the tuberous sclerosis complex (tsc), composed of tsc1/tsc2 heterodimers, is inhibitory to the mammalian target of rapamycin (mtor). |
2011-10-03 |
2023-08-12 |
mouse |
| Philippe Majo. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging. vol 3. issue 3. 2011-08-12. PMID:21415462. |
potential of mtor inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. |
2011-08-12 |
2023-08-12 |
Not clear |
| Philippe Majo. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging. vol 3. issue 3. 2011-08-12. PMID:21415462. |
the tuberous sclerosis complex (tsc) protein is a negative regulator of mtor. |
2011-08-12 |
2023-08-12 |
Not clear |
| Soojeong Kang, Elie R Chemaly, Roger J Hajjar, Djamel Lebech. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. The Journal of biological chemistry. vol 286. issue 21. 2011-07-28. PMID:21478152. |
overexpression of resistin using adenoviral vector in neonatal rat ventricular myocytes was associated with inhibition of amp-activated protein kinase (ampk) activity, activation of tuberous sclerosis complex 2/mammalian target of rapamycin (mtor) pathway, and increased cell size, [(3)h]leucine incorporation (i.e. |
2011-07-28 |
2023-08-12 |
rat |
| Zhao Zhong Chong, Yan Chen Shang, Lijie Zhang, Shaohui Wang, Kenneth Maies. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxidative medicine and cellular longevity. vol 3. issue 6. 2011-07-26. PMID:21307646. |
the signaling pathways of mtor also are believed to be a significant component in a number of neurological diseases, such as alzheimer's disease, parkinson's disease, and huntington's disease, tuberous sclerosis, neurofibromatosis, fragile x syndrome, epilepsy, traumatic brain injury, and ischemic stroke. |
2011-07-26 |
2023-08-12 |
Not clear |
| Shouwei Han, Ying Zheng, Jesse Roma. Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. PPAR research. vol 2007. 2011-07-14. PMID:17597835. |
we set out to test the hypothesis that ppargamma ligands activate tuberous sclerosis complex-2 (tsc2), a tumor suppressor gene that inhibits mtor signaling. |
2011-07-14 |
2023-08-12 |
Not clear |
| Valerio Napolioni, Paolo Curatol. Genetics and molecular biology of tuberous sclerosis complex. Current genomics. vol 9. issue 7. 2011-07-14. PMID:19506736. |
mutations in tsc1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mtor, p70 s6 kinase (s6k), ribosomal protein s6 and the elongation factor binding protein 4e-bp1, resulting in uncontrolled cell growth and tumourigenesis.despite recent promising genetic, diagnostic, and therapeutic advances in tuberous sclerosis complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. |
2011-07-14 |
2023-08-12 |
Not clear |
| Cynthia J Campen, Brenda E Porte. Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. Current treatment options in neurology. vol 13. issue 4. 2011-07-14. PMID:21465222. |
some additional benefits of mtor inhibition in patients with tuberous sclerosis complex, however, may include shrinkage of angiofibromas and angiomyolipomas as well as a possible decrease in seizure burden. |
2011-07-14 |
2023-08-12 |
Not clear |
| François Vigneron, Pierre Dos Santos, Sandrine Lemoine, Maryline Bonnet, Liliane Tariosse, Thierry Couffinhal, Cécile Duplaà, Béatrice Jaspard-Vinass. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovascular research. vol 90. issue 1. 2011-07-11. PMID:21233250. |
a downstream target might be mammalian target of rapamycin (mtor) since wnt can impair tuberous sclerosis complex-2 (tsc2) phosphorylation by inhibiting gsk-3β. |
2011-07-11 |
2023-08-12 |
Not clear |
| David M Feliciano, Tiffany Su, Jean Lopez, Jean-Claude Platel, Angélique Borde. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. The Journal of clinical investigation. vol 121. issue 4. 2011-06-21. PMID:21403402. |
tuberous sclerosis complex (tsc) is an autosomal dominant disorder characterized by mutations in tsc1 or tsc2 that lead to mammalian target of rapamycin (mtor) hyperactivity. |
2011-06-21 |
2023-08-12 |
mouse |
| Robert T Abraha. Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again. F1000 biology reports. vol 1. 2011-06-13. PMID:20948608. |
recent publications have moved us significantly closer to a complete understanding of the mammalian target of rapamycin (mtor) signaling pathway, which plays a central role in the control of growth and metabolism and is dysregulated in a broad spectrum of human diseases, including cancer, tuberous sclerosis, diabetes, and cardiovascular and neurodegenerative diseases. |
2011-06-13 |
2023-08-12 |
human |
| Qian Sun, Xinxin Chen, Jianhui Ma, Haiyong Peng, Fang Wang, Xiaojun Zha, Yanan Wang, Yanling Jing, Hongwang Yang, Rongrong Chen, Long Chang, Yu Zhang, June Goto, Hiroaki Onda, Tong Chen, Ming-Rong Wang, Youyong Lu, Han You, David Kwiatkowski, Hongbing Zhan. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America. vol 108. issue 10. 2011-05-26. PMID:21325052. |
pkm2 level was augmented in mouse kidney tumors due to deficiency of tuberous sclerosis complex 2 and consequent mtor activation, and was reduced in human cancer cells by mtor suppression. |
2011-05-26 |
2023-08-12 |
mouse |
| Juinn-Lin Liu, Zhenyu Mao, Gary E Gallick, W K Alfred Yun. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro-oncology. vol 13. issue 2. 2011-05-09. PMID:21123367. |
because mtor can be alternatively downregulated by tuberous sclerosis complex 2 (tsc2) activation mediated by 5' adenosine monophosphate-activated protein kinase (ampk), we proposed that the activation of ampk α1/2 by lkb1 and/or by calmodulin-dependent protein kinase kinase (camkk) would also block the nuclear export of pten in a manner similar to that of inhibitors of pi3k, mtor, and s6k. |
2011-05-09 |
2023-08-12 |
mouse |
| Whitney E Parker, Ksenia A Orlova, Gregory G Heuer, Marianna Baybis, Eleonora Aronica, Michael Frost, Michael Wong, Peter B Crin. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. The American journal of pathology. vol 178. issue 1. 2011-04-18. PMID:21224066. |
egf, hgf, and vegf modulate the activity of the mammalian target of rapamycin (mtor) cascade, a pathway regulating cell growth that is aberrantly activated in tuberous sclerosis complex (tsc). |
2011-04-18 |
2023-08-12 |
mouse |
| Elizabeth A Barnes, Heidi L Kenerson, Xiuyun Jiang, Raymond S Yeun. Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition. The American journal of pathology. vol 177. issue 4. 2011-03-11. PMID:20813961. |
the tuberous sclerosis complex 2 (tsc2) gene encodes the protein tuberin, which functions as a key negative regulator of both mammalian target of rapamycin (mtor) c1-dependent cell growth and proliferation. |
2011-03-11 |
2023-08-12 |
human |
| Yun-Kyoung Lee, Won Sup Lee, Gon Sup Kim, Ock Jin Par. Anthocyanins are novel AMPKα1 stimulators that suppress tumor growth by inhibiting mTOR phosphorylation. Oncology reports. vol 24. issue 6. 2011-02-24. PMID:21042741. |
ampk functions as an upstream regulator of proliferative signals such as mammalian target of rapamycin (mtor), tuberous sclerosis complex (tsc), p70s6 and elongation factor-2, indicating that ampk can be applied for the inhibition of cancer cell proliferation via modulating the proliferative signaling network. |
2011-02-24 |
2023-08-12 |
Not clear |
| Ramón Peces, Carlos Peces, Emilio Cuesta-López, Virginia Pérez-Dueñas, Cristina Vega-Cabrera, Sebastián Azorín, Rafael Selga. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. vol 25. issue 11. 2011-02-01. PMID:20663789. |
tuberous sclerosis complex (tsc) is caused by constitutively activated mammalian target of rapamycin (mtor) resulting in non-malignant tumours of several organs including renal angiomyolipomas (amls). |
2011-02-01 |
2023-08-12 |
Not clear |
| Magdalena Ewa Tyburczy, Katarzyna Kotulska, Piotr Pokarowski, Jakub Mieczkowski, Joanna Kucharska, Wieslawa Grajkowska, Maciej Roszkowski, Sergiusz Jozwiak, Bozena Kaminsk. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. The American journal of pathology. vol 176. issue 4. 2010-12-14. PMID:20133820. |
novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
2010-12-14 |
2023-08-12 |
human |
| Magdalena Ewa Tyburczy, Katarzyna Kotulska, Piotr Pokarowski, Jakub Mieczkowski, Joanna Kucharska, Wieslawa Grajkowska, Maciej Roszkowski, Sergiusz Jozwiak, Bozena Kaminsk. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. The American journal of pathology. vol 176. issue 4. 2010-12-14. PMID:20133820. |
subependymal giant cell astrocytomas (segas) are rare brain tumors associated with tuberous sclerosis complex (tsc), a disease caused by mutations in tsc1 or tsc2, resulting in enhancement of mammalian target of rapamycin (mtor) activity, dysregulation of cell growth, and tumorigenesis. |
2010-12-14 |
2023-08-12 |
human |